Research Center: TrialsWest
Locations: TrialsWest Spearwood, 6 Barrington Street, Spearwood, WA, 6163, and TrialsWest Osborne Park, 226 Main Street, Osborne Park, WA, 6017
Lead Researcher: Professor Peter Bremner
Ethics Approval: These studies have been reviewed and approved by the Bellberry Human Research Ethics Committee

Living with bronchiectasis can be frustrating. Constant coughing, mucus build-up, and repeated infections can take a toll on your daily life. Current treatments don’t always provide enough relief, which is why researchers are exploring new options.

TrialsWest Spearwood and TrialsWest Osborne Park are currently seeking people with bronchiectasis to participate in one of the two clinical trials on offer. The purpose of these trials is to test two different potential new treatments to see if they can reduce inflammation, reduce breathlessness, and help prevent flare-ups in patients with bronchiectasis. In each clinical trial, participants will be randomly assigned to receive either the study medicine or a placebo (inactive medicine).

Take the next step, see if you qualify today, and be part of a clinical trial that could change the future of bronchiectasis care.

• Participants will be compensated for taking part in this study. Reimbursements are offered for travel costs at each visit.
• Participants may experience improvements in their bronchiectasis symptoms such as coughing and sputum production, and have a decrease in the number of times they need to receive antibiotic treatment for flare-ups of their symptoms.
• Participants will be contributing valuable information that may help improve treatment options for people with bronchiectasis in the future.
• Participants will be helping to advance medical research.

• You will receive a detailed outline of all details of the study, including treatment, risks, and procedures, and you will be given the chance to ask study staff questions before you decide whether to participate.
• If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.

Eligible:

• Adults aged 18 to 85 years of age
• Must have a primary diagnosis of bronchiectasis (Bronchiectasis) confirmed by a chest CT scan within the past 12 months, or be willing to have one during screening.
• Must have taken at least one course of antibiotics to treat bronchiectasis in the past 12 months and either:
  • Be currently experiencing bronchiectasis symptoms (e.g., cough, sputum production, change in sputum colour, breathlessness, decreased ability to exercise, and/or fatigue) if only one course of antibiotics was required, or
  • have had two or more exacerbations requiring antibiotics in the past 12 months (symptoms not required if this criterion is met).
• Must be able to follow study instructions and attend all study visits.

Ineligible

• Must not have had a lung transplant or be on a waiting list for one.
• Must not have other major lung diseases (like pulmonary fibrosis or diffuse panbronchiolitis).
• Must not have severe heart problems, such as a recent heart attack, stroke, or heart failure.
• Must not currently be treated for tuberculosis, NTM lung disease, or allergic fungal lung infection.
• Must not have had cancer in the past 5 years (except certain early-treated skin or cervical cancers).
• Must use effective contraception if of childbearing potential (or have a partner of childbearing potential).
• Must not be a current smoker, have quit less than 6 months ago, or have a heavy smoking history (>10 pack-years).
• Must not have a history of severe allergic reactions to similar treatments.
• Must weigh at least 40 kg (about 88 lbs).
• Must not be participating in another clinical trial or have taken another investigational drug recently.

TrialsWest
Established in 2012, TrialsWest is one of Australia’s most experienced and successful clinical research organisations. TrialsWest, with locations in Spearwood, Osborne Park, and Mandurah in Perth, Western Australia, partners with the world’s leading pharmaceutical and biotechnology companies to help bring new medicines and vaccines to the world.